Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 85

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 85
---
, the Civil Code dated December 8, 2017 as amended by the Law on Implementation of the Civil Code dated May 31, 2011, Law on Management of Donation and Transplantation of Human Cells, Tissues, and Organs (2016) and Sub-Decree No. 61 on the Code of Medical Ethics (2003) in Cambodia and Constitution of Kyrgyzstan of May 5, 2021, Civil Code, Part I of May 8, 1996 No. 15, Law on Health Protection of Civilians of Kyrgyzstan of January 9, 2005 No. 6, Law on Reproduction Rights and on Guarantees of their Realization of July 4, 2015 No. 148, Law on status of medical worker of May 28, 2013 No. 81 and other relevant applicable laws in Kyrgyzstan, which enables consumers and patients to file suits more easily against healthcare service providers. Furthermore, treatment of more complex medical conditions has no guaranteed positive outcome, which subjects it to an increased likelihood of medical malpractice suits. Such lawsuits could result in hefty compensation payments or damage to NewGenIvf’s reputation, which may have a material adverse effect on its business, financial condition, results of operations and prospects. |

Meanwhile, Thailand is considering
enacting a Patient Protection Bill (the “Bill”). The Bill, if issued, is intended to alleviate disputes between patients
and healthcare providers, which have an impact on the healthcare system in Thailand as a whole. The compensation outlined in the Bill
will assist patients in claiming damages, thereby fostering a positive relationship between patients and healthcare providers. Consequently,
the rate of disputes is expected to decrease. The provisions under the Bill would require healthcare providers to compensate patients
in a timely manner, sometimes without requiring proof of wrongdoing. The Bill also contemplates setting up a patient protection fund for
damages to patients pursuant to which healthcare providers have to make mandatory contributions according to the rules determined by a
patient protection committee. Failure by it to comply with applicable rules and regulations could result in penalties, the loss of regulatory
permits and damage to NewGenIvf’s business reputation, each of which could have a material adverse effect on its financial condition
and results of operations.

Furthermore, the Protection of A Child
Born By Medically Assisted Reproductive Technology Act B.E. 2558 (2015) of Thailand was promulgated with the intention to appropriately
designate